Abstract
More than 2 million Americans use cocaine each month (National Survey on Drug Use and Health, Department of Health and Human Services: Substance Abuse and Mental Health Services Administration (SAMHSA) & Office of Applied Studies (OAS), Rockville, MD 2007). Starting in early 2003, South American cocaine cartels began to add levamisole, a pharmaceutical agent, to bulk cocaine prior to shipment to the USA (Valentino and Fuentecilla 2005). A dramatic increase in the prevalence of levamisole in cocaine was noted in early 2008. By October, 30% of cocaine bricks analyzed by the United States Drug Enforcement Administration contained levamisole (Casale et al. 2008). Exposure to levamisole can cause agranulocytosis (Amery and Bruynseels 1992). We report the first confirmed case of agranulocytosis associated with consumption of levamisole-contaminated cocaine in the USA. A previously healthy adult male presented to the emergency department with 5 days of mouth pain. He admitted to chronic active ethanol and crack cocaine abuse. Laboratory studies revealed severe neutropenia, with an absolute neutrophil count of 19 cells/mm3 (normal = 1,500–8,000 cells/mm3). A urine screen for drugs of abuse was positive for cocaine metabolites and opiates. Evaluation of a peripheral blood smear showed leukopenia with severe absolute neutropenia. A bone marrow biopsy revealed recently injured bone marrow showing early recovery. While in the hospital, the patient had little spontaneous bone marrow recovery. He received granulocyte colony-stimulating factor with improvement in peripheral white blood cell counts. The residue in the patient’s crack pipe contained 10% levamisole. Subsequently, levamisole was detected in the patient’s urine. Levamisole-associated agranulocytosis should be considered in the diagnosis of patients who present with neutropenia and a history or evidence of cocaine use.
Keywords: Levamisole, Agranulocytosis, Cocaine
Full Text
The Full Text of this article is available as a PDF (260.2 KB).
Acknowledgments
Funding
None.
References
- 1.National Survey on Drug Use and Health, Department of Health and Human Services: Substance Abuse and Mental Health Services Administration (SAMHSA) & Office of Applied Studies (OAS), Rockville, MD 2007. Accessed on April 5, 2009, at http://oas.samhsa.gov/NSDUH/2k7NSDUH/2k7results.cfm#Ch2.
- 2.Valentino AMM, Fuentecilla K. Levamisole: an analytical profile. Microgram J. 2005;3(3–4):134–137. [Google Scholar]
- 3.Casale JF, Corbeil EM, Hays PA. Identification of levamisole impurities found in illicit cocaine exhibits. Microgram J. 2008;6(3–4):82–89. [Google Scholar]
- 4.Amery WKP, Bruynseels JPJM. Levamisole, the story and the lessons. Int J Immunopharm. 1992;14(3):481–486. doi: 10.1016/0192-0561(92)90179-o. [DOI] [PubMed] [Google Scholar]
- 5.National Institute on Drug Awareness, NIH, & US Department of Health & Human Services, NIDA Info Facts, August 2008. Accessed on April 5, 2009 at http://www.nida.nih.gov/infofacts/cocaine.html
- 6.Lintemoot J (2005) Drugs in the news: levamisole: an unusual finding in a cocaine related fatality. December, 2005. Accessed on April 5, 2009 at http://www.cal-tox.org/Downloads/Monographs/Levamisole.pdf
- 7.Rongioletti F, Ghio L, Ginevri F, et al. Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol. 1999;140:948–951. doi: 10.1046/j.1365-2133.1999.02833.x. [DOI] [PubMed] [Google Scholar]
- 8.Levamisole. In: DRUGDEX® system. Greenwood Village, CO: Thomson Health-care. Accessed on April 5, 2009.
- 9.Ibáñez L, Vidal X, Ballarín E, Laport JR. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165(8):869–874. doi: 10.1001/archinte.165.8.869. [DOI] [PubMed] [Google Scholar]
- 10.Zhu NY, LeGatt DF, Turner AR. Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Intern Med. 2009;150(4):287–289. doi: 10.7326/0003-4819-150-4-200902170-00102. [DOI] [PubMed] [Google Scholar]
- 11.New Mexico Department of Health (2009) Department of Health investigates unusual condition that harms immune system potential cocaine contamination could be cause; January 16, 2009. Accessed on April 5, 2009 at http://www.nmhealth.org/documents/agranulocytosis1-16-09.pdf
- 12.Gostic T, Klemenc S, Stefane B. A study of the thermal decomposition of adulterated cocaine samples under optimized aerobic pyrolitic conditions. Forensic Sci Int. 2009;187:1–3. doi: 10.1016/j.forsciint.2009.02.009. [DOI] [PubMed] [Google Scholar]
- 13.Schmidt KL, Mueller-Eckhardt C. Agranulocytosis, levamisole and HLA-B27. Lancet. 1977;2(8028):85. doi: 10.1016/s0140-6736(77)90082-4. [DOI] [PubMed] [Google Scholar]
- 14.Fucci N. Unusual adulterants in cocaine seized on Italian clandestine market. Forensic Sci Int. 2007;172:e1. doi: 10.1016/j.forsciint.2007.05.021. [DOI] [PubMed] [Google Scholar]
- 15.Morley SR, Forrest ARW, Galloway JH (2006) Levamisole as a contaminant of illicit cocaine. Toxicology Section, Sheffield Teaching Hospital Foundation Trust, Sheffield 2006. Accessed on April 5 2009 at from http://www.tiaft2006.org/proceedings/pdf/PT-p-06.pdf
- 16.Chung S, Hopf FW, Nagasaki H et al (2009) The melanin-concentrating hormone system modulates cocaine reward. Proc Natl Acad Sci 106(16) 6772–6777 [DOI] [PMC free article] [PubMed]
- 17.Spector S, Munjai I, Schmidt DE. Effects of the immunostimulant, levamisole, on opiate withdrawal and levels of endogenous opiate alkaloids and monoamine neurotransmitters in rat brain. Neuropsychopharmacology. 1998;19:417–427. doi: 10.1016/S0893-133X(98)00034-7. [DOI] [PubMed] [Google Scholar]
- 18.Andrès E, Zimmer J, Affenberger S, Frederici L, Alt M, Maloisel F. Idiosyncratic drug-induced agranulocytosis: update of an old disorder. Europ J Intern Med. 2006;17:529–535. doi: 10.1016/j.ejim.2006.07.012. [DOI] [PubMed] [Google Scholar]
- 19.Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;149(9):657–665. doi: 10.7326/0003-4819-146-9-200705010-00009. [DOI] [PubMed] [Google Scholar]